626 results about "Pharmacologic effects" patented technology

Hemostatic agents and devices are made from oxidized cellulose fiber, the oxidized cellulose having a carboxylation content increased by the action of nitrogen dioxide on virgin cellulose fiber. A composition may be incorporated into the oxidized cellulose fiber to cause a pharmacological effect on a wound to which the hemostatic agents and devices are applied. When applied, the oxidized cellulose fiber causes blood emanating from the wound to clot. The oxidized cellulose fiber can either be resorbed into the wound or removed from the wound after healing. A hemostatic bandage includes a pad of unwoven oxidized cellulose fibers mounted on a substrate. Methods of arresting a flow of blood emanating from a wound using such devices are also disclosed. Methods of fabricating oxidized cellulose are also disclosed.

The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.

The present invention relates to extraction process of total tanshin phenolic acid, the preparation process and application of its preparation. The total tanshin phenolic acid and its preparation mayuse in preparing medicine for preventing and treating cardiac and cerebral vascular diseases, senile dementia and hypomnesia caused by cerebral ischemia. The total tanshin phonelic acid prepared based on the process of the present invention has rich active components of tanshin and obvious pharmacological effect, stable performance and les stoxicity and is safety and reliable.

A two-stage medicine delivery system provides an initial dose of medicine and a second dose of medicine. The initial and second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively. The two-stage medicine delivery system preferably delivers a craving reduction substance, in which case, the rapid and prolonged pharmacological effects include a rapid and prolonged craving reduction. Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form. The two-stage medicine delivery system preferably releases a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth. A method of making the medicine delivery system also is provided. The system and apparatus can be adapted to reduce cravings for alcohol, food, drugs (e.g., cocaine, opiates and the like) and tobacco products, especially tobacco products containing nicotine.

The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used to enhance vaccination, increase synthesis of and enhance function of blood cell components and enhance anti-neoplastic effects of various agents. The compounds of the invention can be used to produce a variety of further pharmacologic effects.

The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin; 2°. exerting said inhibitory effect on inflammatory response to an external stimulus even under conditions of oxidative stress, 3°. exerting a local immuno-modulating and anti-inflammatory effect in the intestine, thus preventing intestinal damage induced by a non-steroid anti-inflammatory drug (NSAIDs), 4°. exerting an immuno-modulating and anti-inflammatory effect in human intestinal cells in vitro, 5°. alleviating pulmonary symptoms, such as shortness of breath and dyspnoea, in patients suffering from an obstructive pulmonary disease, and 6°. exerting favorable clinical effects with respect to certain mental and neurological disorders and aberrant conditions. The medicine is preferably manufactured in lyophilized form.

A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the sparingly water-soluble anticancer agent, and diminishes the side effects of the anticancer agent. Provided are: a novel block copolymer which can be a drug carrier having no harmful side effects such as hypersensitive reaction; a micelle preparation in which micelles are formed and which contains a sparingly water-soluble anticancer agent, especially paclitaxel, incorporated in the micelles in an amount necessary for a disease treatment without bonding it to the block copolymer and which can heighten the solubility of the drug in water; and an anticancer agent which comprises the micelle preparation as a medical ingredient, maintains a high concentration in the blood, has more potent drug activity, and is reduced in toxicity.

The present invention relates to a novel purpose of timosaponin B-II. The anti-depression test of the timosaponin B-II in total timosaponin extract shows obvious anti-depression activity; The present invention has strong pharmacological effect and stable quality; the raw material of the present invention has abundant source, cheap price and is safe with low toxin; the present invention has simple preparation technology and high yield, which provides a novel medicine source for preventing, diagnosing, examining, protecting, remedying and researching on the depression and diseases directly related to the depression, is fit for the industrialization production, is easy for popularizing, applying and has very important value for developing and using Chinese officinal plant resource. Affective mental disorder is listed at top in Chinese disease general burden, and the research and manufacture of the drug for preventing and remedying the depression has obvious social benefit and economic benefit.

The invention discloses a manufacturing method of a poultry feed additive containing traditional Chinese medicinal activity probiotics, comprising the following steps of: carrying out single stain quantity enlarge culture on the original strain of every poultry activity probiotic; mixing equal weight first-level seed liquids of each poultry activity probiotic, inoculating to a medium in a seed jar for mixing and culturing of a plurality of strains, and inoculating into a traditional Chinese medicinal liquid medium for the fermentation of the traditional Chinese medicine so as to prepare the poultry feed additive containing traditional Chinese medicinal activity probiotics. The embodiment provided by the invention can be implemented to greatly raise the strain activity of activity probiotics in the poultry feed additive and the colonization performance in intestinal tract, make the prepared poultry feed additive rich in traditional Chinese medicinal components and make the active components with pharmacological effects in the traditional Chinese medicinal components to fully perform, so as to raise the poultry feed additive's body strengthening and disease treating performance and growth promotion performance. Furthermore, antibiotics are completely replaced.

A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic defects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist. In another embodiment, the drug or its other agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and antagonist.

A pharmaceutical composition for treating or preventing a disease, condition or symptoms thereof in a warm-blooded animal including a human, includes a therapeutically effective amount of an opioid agonist exhibiting potential pharmacologically addictive properties in warm blooded animals including humans; a side-effect reducing agent present in amounts sufficient to at least substantially neutralize the adverse side effects of the opioid agonist; an opioid antagonist present in a sequestered form in amounts sufficient to block the pharmacological effect of the opioid agonist upon release from the sequestered form; and a pharmaceutically acceptable carrier.

In this invention, first It is set that an object of study of a compound traditional Chinese medicine with its chemical compositions being clear about. The molecules of chemical constitutions of each ingredient of the Chinese medicine prescription are collected and reorganized, and setting a data base for chemical constitutions molecules of said Chinese medicine prescription. For the aim of pharmacodynamics effects of main therapeutical functions of the traditional Chinese medicine prescription with their clear therapeutical effects, clear mechanism and definited target spots, we search or set up the corresponding molecular target spots. Three procedures (without odor of priority) are: poisonousness sieving, analogous medicine properties estimation and molecular abutment decision to these molecular data base of the set pharmacodynamics models respectively. Finally we estimating all the molecules in the molecular data base, selecting-out the molecules with higher grading, to obtain the pharmacodynamics effect P(i) molecular pre-prescription, and then producing novel prescriptions.

The invention discloses a poloxamer-carboxylic acid drug conjugate and a preparation method and application thereof. The conjugate is formed by directly linking the carboxyl of the carboxylic acid drug with the carboxyl of the poloxamer by the ester bond in the presence of a catalyst. The conjugate is the compound in the general formula (i) or (ii). Compared with the original carboxylic acid drugs, the conjugate has greatly improved drug solubility, enhanced pharmacological effects, reduced adverse reaction and higher safety. By utilizing the hydrophobic carboxylic acid drug, the conjugate can enhance the hydrophobicity of the poloxamer and greatly improve the amphipathy of the poloxamer, thus being capable of forming stable micellar structure under waterborne environment. As the drug carrier, the conjugate can complete further encapsulation of the drugs and can meet different release requirements by controlling the chemical grafted amount and the physical encapsulation amount or realize combined therapy of the drugs by physically embedding other pharmaceutically active drugs. The invention has simple preparation method, mature process and high yield and is suitable for industrialproduction.

The present invention relates to the active general flavone components extracted from longbract cattail as one kind of Chinese medicinal materials. The extractive includes mainly isorhamnetin, quercetin, kaempferol and their glycoside derivatives, and also includes the degraded products of the said components, their metal salt derivatives, metal complexes, etc. The extractive may be obtained via solvent extraction process and other process. The extractive has the functions of lowering blood fat, resisting atherosclerosis, raising the tolerance of cardiac and cerebral tissues to deficiency of oxygen and blood, resisting platelet aggregation, etc. and may be used in preventing and treating cardiac and cerebral vascular diseases, traumatic injury, haemorrhages and other diseases.

The invention discloses an application of suaeda glauce plant extractive for preparing fat-reducing health-care food, wherein the stem and germ of suaeda glauce have been proved with fat-reducing function, and compared with present fat-reducing drug, they have significant pharmacological function, non side effect and significant fat-reducing effect. The inventive suaeda glauce plant extractive is natural, with abundant resource, low cost, and simple process, while it can be made into kinds of health-care food.

Provided is a pharmaceutical agent capable of efficiently improving blood circulation in a region where a circulatory disorder occurs and fully preventing or improving tissue damage as a preventive or therapeutic agent for circulatory disorders in general. As a result of the study of pharmacological effects of a compound in which a porphyrin metal complex is clathrated in albumin, it was found that the compound efficiently improves decreases in blood flow in circulatory disorders and fully prevents or improves tissue damage, thus the invention was achieved. That is, the invention is directed to an agent for improving a circulatory disorder including a compound in which a porphyrin metal complex is clathrated in albumin.

The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a pH-independent material in combination.

The invention relates to a novel tryptanthrin (indole[2,1-b] quinazoline-6,12-diketone) derivative, a synthetic method and a medicinal application thereof. A general structural formula is as follows (see the description). The novel tryptanthrin derivative is synthesized through biomimetic synthesis, the general chemical structural formula of the novel derivative is shown in Figure 1, wherein in the formula, R,R1,R2,R3 are halogen, nitro, amido, hydroxy, alkyl, alkoxy and aryl, R1is morpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, isonipecotic acid, piperazine, 1-(2-pyridyl) piperazine, dimethylamine, diethylamine, 1-(2-ethoxy) piperazine and 1-(2-furoyl) piperazine, and an o-aminobenzoic acid derivative reacts with an indole quinone derivative in solvents of methylbenzene, methyl alcohol, ethyl alcohol, dichloromethane, isopropanol and the like, so as to prepare the novel tryptanthrin derivative. The novel tryptanthrin derivative which has a good inhibiting effect and a good antibacterial effect on cancer cells is preliminarily screened through an MTT experiment and an antibacterial experiment, and the medicine has pharmacological effects in the aspects of tumor resistance, antibiosis and inflammation diminishing.

The invention relates to the technical field of medical apparatus. The generation of ventilator-associated pneumonia is the result of the inspiration of secretion with pathogen, wherein the bacterialcontamination in a ventilator air tube is also a principal element for causing the ventilator-associated pneumonia. The invention aims to provide a manual tracheotomy tube with broad spectrum of antimicrobial activity and controllable slow-release medicaments, comprising a flexible tube body and a tampon system attached to the outside of the tube body, wherein the inner surface and the outer surface of the tracheotomy tube are combined with macromolecular polymer antimicrobial coatings in which medicaments with pharmacologic effect are loaded. The invention not only achieves the efficacy of providing air paths for a traditional tracheotomy tube and keeping the respiratory tract smooth, but also has excellent bacteriostatic effect and the slow release effect of the controllable medicaments,thereby providing a wide application prospect for clinical application of the manual tracheotomy tube.